S-1033

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 466085

CAS#: 138282-73-2 (sodium)

Description: S-1033 is an FP receptor agonist.

Chemical Structure

img
S-1033
CAS# 138282-73-2 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 466085
Name: S-1033
CAS#: 138282-73-2 (sodium)
Chemical Formula: C20H33NaO4
Exact Mass: 360.23
Molecular Weight: 360.470
Elemental Analysis: C, 66.64; H, 9.23; Na, 6.38; O, 17.75

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: S-1033; S1033; S 1033;

IUPAC/Chemical Name: sodium (E)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((E)-oct-1-en-1-yl)cyclopentyl)hept-5-enoate

InChi Key: WESGECMANBOOPN-ADIIAVBHSA-M

InChi Code: InChI=1S/C20H34O4.Na/c1-2-3-4-5-6-9-12-16-17(19(22)15-18(16)21)13-10-7-8-11-14-20(23)24;/h7,9-10,12,16-19,21-22H,2-6,8,11,13-15H2,1H3,(H,23,24);/q;+1/p-1/b10-7+,12-9+;/t16-,17-,18-,19+;/m1./s1

SMILES Code: O=C([O-])CCC/C=C/C[C@@H]1[C@@H](/C=C/CCCCCC)[C@H](O)C[C@@H]1O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 360.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. doi: 10.1089/108076803322660422. PMID: 14733708.

2: Ando Y, Matsunami C, Yamamoto T, Kitazawa Y. [Safety and ocular hypotensive effect of a new prostaglandin analogue, S-1033, in normal volunteers]. Nippon Ganka Gakkai Zasshi. 1994 Nov;98(11):1109-14. Japanese. PMID: 7825505.

3: Higaki K, Kamata K, Takeuchi M, Inazawa K, Chikai T, Hamaguchi T, Yukawa T, Kadono K, Kawahara S, Nakano M. Ocular absorption, distribution, and systemic absorption of a novel antiglaucoma medication, prostaglandin derivative, in male white rabbits. Drug Metab Dispos. 1995 Jan;23(1):35-43. PMID: 7720522.

4: Kominami G, Nakamura M, Mizobuchi M, Ueki K, Kuroda T, Yamauchi A, Takahashi S. Radioimmunoassay and gas chromatography/mass spectrometry for a novel antiglaucoma medication of a prostaglandin derivative, S-1033, in plasma. J Pharm Biomed Anal. 1996 Nov;15(2):175-82. doi: 10.1016/0731-7085(96)01849-3. PMID: 8933419.

5: Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 1997 Feb;41 Suppl 2:S69-75. doi: 10.1016/s0039-6257(97)80010-0. PMID: 9154279.

6: Sharif NA, Kelly CR, Crider JY. Agonist activity of bimatoprost, travoprost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptor. J Ocul Pharmacol Ther. 2002 Aug;18(4):313-24. doi: 10.1089/10807680260218489. PMID: 12222762.

7: Sharif NA, Kelly CR, Crider JY. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest Ophthalmol Vis Sci. 2003 Feb;44(2):715-21. doi: 10.1167/iovs.02-0323. PMID: 12556403.

8: Sharif NA, Crider JY, Husain S, Kaddour-Djebbar I, Ansari HR, Abdel-Latif AA. Human ciliary muscle cell responses to FP-class prostaglandin analogs: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation. J Ocul Pharmacol Ther. 2003 Oct;19(5):437-55. doi: 10.1089/108076803322473006. PMID: 14583136.

9: Sharif NA. Synthetic FP-prostaglandin-induced contraction of rat uterus smooth muscle in vitro. Prostaglandins Leukot Essent Fatty Acids. 2008 Mar;78(3):199-207. doi: 10.1016/j.plefa.2008.01.005. Epub 2008 Mar 28. PMID: 18375109.

10: Sharif NA, Kaddour-Djebbar I, Abdel-Latif AA. Cat iris sphincter smooth- muscle contraction: comparison of FP-class prostaglandin analog agonist activities. J Ocul Pharmacol Ther. 2008 Apr;24(2):152-63. doi: 10.1089/jop.2007.0076. PMID: 18355130.